Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | MAG | P20916 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PRKCA | P17252 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | FGF1 | P05230 | 2/20 | 0.35 |
| ▸ | FGF2 | P09038 | 2/20 | 0.35 |
| ▸ | VEGFA | P15692 | 2/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.35 |
| ▸ | SELP | P16109 | 3/20 | 0.35 |
| ▸ | SELL | P14151 | 2/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | HRAS | P01112 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17173994 | 0.86 | SLC6A2 (0.52) | SLC6A2LGALS8L3MBTL1PRKCAKDM1A | |
| SCHEMBL19658823 | 0.85 | SLC6A2 (0.45) | SLC6A2MAGLGALS8LGALS3HRAS | |
| SCHEMBL19652045 | 0.85 | SLC6A2 (0.45) | SLC6A2MAGLGALS8LGALS3HRAS | |
| SCHEMBL7154227 | 0.83 | SLC6A2 (0.44) | SLC6A2LGALS8 | |
| SCHEMBL7642620 | 0.83 | SLC6A2 (0.44) | SLC6A2LGALS8 | |
| SCHEMBL9073779 | 0.81 | ALDH1A1 (0.48) | SLC6A2FGF1FGF2VEGFAHPSE | |
| SCHEMBL8741450 | 0.81 | ALDH1A1 (0.48) | SLC6A2FGF1FGF2VEGFAHPSE | |
| SCHEMBL18570422 | 0.80 | SLC6A2 (0.53) | SLC6A2LGALS8L3MBTL1PRKCAKDM1A | |
| SCHEMBL19669777 | 0.80 | SLC6A2 (0.53) | SLC6A2LGALS8L3MBTL1PRKCAKDM1A | |
| SCHEMBL19652050 | 0.78 | SLC6A2 (0.53) | SLC6A2LGALS8L3MBTL1PRKCAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834574-B2 | Crystalline 3-O-fucosyllactose | GLYCOM A/S (DK) | 2017-12-05 | — | — | US | disclosed |
| US-20150291642-A1 | CRYSTALLINE 3-O-FUCOSYLLACTOSE | GLYCOM A/S (DK) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291642-A1 | CRYSTALLINE 3-O-FUCOSYLLACTOSE | FUCA2, FUT6, FUCA1 | SLC6A2 2365/4885MAG 748/4885LGALS8 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.